New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > HSCT Allogeneic conditioning Reduced intensity Haploidentical - Flu/Cy/TBI 2Gy with PTCy [fludarabine, CYCLOPHOSPHamide and total body irradiation 2Gy with post-transplant CYCLOPHOSPHamide]

HSCT Allogeneic conditioning Reduced intensity Haploidentical - Flu/Cy/TBI 2Gy with PTCy [fludarabine, CYCLOPHOSPHamide and total body irradiation 2Gy with post-transplant CYCLOPHOSPHamide]

Treatment Overview

Cycle 1 - 35 days

Cycle length:
35

Hydration in addition to that specified is recommended as per institutional practice and may need an individualised approach.


CYCLOPHOSPHamide:

  • Dose adjustment for patients weight may be required.
  • See Dosing for bodyweight in Additional details.
  • Refer to latest literature or access https://anztct.org.au (registration required).
  • Monitor for syndrome of inappropriate secretion of ADH with high dose CYCLOPHOSPHamide.

mycophenolate mofetil: Continue until Day 35, then stop.


ciclosPORIN:

  • Adjust dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for graft versus host disease (GVHD) prophylaxis to be continued, duration as per haematologist advice.

Cycle details

Cycle 1 - 35 days

Medication / Procedure Dose Route Days Max Duration
fludarabine * 30 mg/m² Once daily intravenous -6 to -2 60 minutes
CYCLOPHOSPHamide * 14.5 mg/kg Once daily intravenous -6, -5 60 minutes
Total body irradiation 2 Gy -1
paracetamol * 1000 mg flat dosing oral administration 0
proMETHazine * 12.5 mg intravenous 0 1 minutes
Allogeneic stem cell transplant intravenous 0
mesna * 50 mg/kg Once daily intravenous 3, 4 24 hours
sodium chloride 0.9 % intravenous 3, 4 120 minutes
CYCLOPHOSPHamide * 50 mg/kg Once daily intravenous 3, 4 120 minutes
sodium chloride 0.9 % intravenous 3, 4 120 minutes
mycophenolate mofetil * 15 mg/kg Three times daily oral administration 5 to 35
ciclosPORIN * 1.5 mg/kg Twice daily intravenous 5 to 8 Min: 120 minutes
ciclosPORIN * [Dose - see details] Twice daily intravenous 9 to 35 Min: 120 minutes

Hydration in addition to that specified is recommended as per institutional practice and may need an individualised approach.


CYCLOPHOSPHamide:

  • Dose adjustment for patients weight may be required.
  • See Dosing for bodyweight in Additional details.
  • Refer to latest literature or access https://anztct.org.au (registration required).
  • Monitor for syndrome of inappropriate secretion of ADH with high dose CYCLOPHOSPHamide.

mycophenolate mofetil: Continue until Day 35, then stop.


ciclosPORIN:

  • Adjust dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for graft versus host disease (GVHD) prophylaxis to be continued, duration as per haematologist advice.

Full details

Cycle 1 - 35 days

Day: -6

Medication Dose Route Max duration Details
fludarabine * 30 mg/m² Once daily intravenous 60 minutes Additional details:
CYCLOPHOSPHamide * 14.5 mg/kg Once daily intravenous 60 minutes
Instructions:

Dose adjustment for patients weight may be required, see Dosing for bodyweight, below.

Additional details:

Day: -5

Medication Dose Route Max duration Details
fludarabine * 30 mg/m² Once daily intravenous 60 minutes Additional details:
CYCLOPHOSPHamide * 14.5 mg/kg Once daily intravenous 60 minutes
Instructions:

Dose adjustment for patients weight may be required, see Dosing for bodyweight, below.

Additional details:

Day: -4

Medication Dose Route Max duration Details
fludarabine * 30 mg/m² Once daily intravenous 60 minutes Additional details:

Day: -3

Medication Dose Route Max duration Details
fludarabine * 30 mg/m² Once daily intravenous 60 minutes Additional details:

Day: -2

Medication Dose Route Max duration Details
fludarabine * 30 mg/m² Once daily intravenous 60 minutes Additional details:

Day: -1

Medication / Procedure Dose Route Max duration Details
Total body irradiation 2 Gy
Instructions:

Administer as one fraction or as per institutional practice.

Day: 0

Medication / Procedure Dose Route Max duration Details
paracetamol * 1000 mg flat dosing oral administration
Instructions:

ONE hour prior to return of allogeneic stem cells, or as per institutional practice.
proMETHazine * 12.5 mg intravenous 1 minutes
Instructions:

ONE hour prior to return of allogeneic stem cells, or as per institutional practice.
Allogeneic stem cell transplant intravenous
Instructions:

Administer as per institutional practice.

Day: 3

Medication Dose Route Max duration Details
mesna * 50 mg/kg Once daily intravenous 24 hours
Instructions:

Continuous infusion over 24 hours.

  • Commence ONE hour before the first dose of CYCLOPHOSPHamide and continue for 24 hours after the last dose of CYCLOPHOSPHamide, or as per institutional practice.
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

Prior to CYCLOPHOSPHamide infusion.
CYCLOPHOSPHamide * 50 mg/kg Once daily intravenous 120 minutes
Instructions:
  • Dose adjustment for patients weight may be required, see Dosing for bodyweight, below.
  • Consider hydration in addition to that specified to achieve 3000 ml/m2/24 hours is recommended on days of high dose CYCLOPHOSPHamide and for 24 hours after, or as per institutional practice.
Additional details:
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

After CYCLOPHOSPHamide infusion.

Day: 4

Medication Dose Route Max duration Details
mesna * 50 mg/kg Once daily intravenous 24 hours
Instructions:

Continuous infusion over 24 hours.

  • Commence ONE hour before the first dose of CYCLOPHOSPHamide and continue for 24 hours after the last dose of CYCLOPHOSPHamide, or as per institutional practice.
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

Prior to CYCLOPHOSPHamide infusion.
CYCLOPHOSPHamide * 50 mg/kg Once daily intravenous 120 minutes
Instructions:
  • Dose adjustment for patients weight may be required, see Dosing for bodyweight, below.
  • Consider hydration in addition to that specified to achieve 3000 ml/m2/24 hours is recommended on days of high dose CYCLOPHOSPHamide and for 24 hours after, or as per institutional practice.
Additional details:
sodium chloride 0.9 % intravenous 120 minutes
Quantity:1000 mL
Instructions:

After CYCLOPHOSPHamide infusion.

Day: 5

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * 1.5 mg/kg Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Adjust dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.

Day: 6

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * 1.5 mg/kg Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Adjust dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.

Day: 7

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * 1.5 mg/kg Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Adjust dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.

Day: 8

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * 1.5 mg/kg Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Adjust dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.

Day: 9

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 10

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 11

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 12

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 13

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 14

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 15

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 16

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 17

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 18

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 19

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 20

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 21

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 22

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 23

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 24

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 25

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 26

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 27

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 28

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 29

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 30

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 31

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 32

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 33

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 34

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued, duration as per haematologist advice.

Day: 35

Medication Dose Route Max duration Details
mycophenolate mofetil * 15 mg/kg Three times daily oral administration
Instructions:

Stop after Day 35.

  • Do not take indigestion remedies, iron or calcium preparations within 2 hours of taking this medicine.
ciclosPORIN * [Dose - see details] Twice daily intravenous Min: 120 minutes
Instructions:

Every 12 hours.

  • Dose according to trough levels as per institutional practice.
  • Switch to oral therapy when tolerated, ensure correct conversion between IV and oral therapy.
  • Oral ciclosPORIN for GVHD prophylaxis to be continued past day 35, duration as per haematologist advice.

Additional details

Section 1: Dosing for bodyweight

Supportive Care Factors

Factor Value
Antifungal prophylaxis: Routine antifungal prophylaxis recommended
Antiviral prophylaxis for hepatitis B virus: Required for anti–HBc positive patients at risk of reactivation
Antiviral prophylaxis for herpes virus: Routine antiviral prophylaxis recommended
CMV monitoring: Recommended
Emetogenicity: Variable
Gastroprotection: Gastroprotection may be considered
Graft versus host disease prophylaxis: Graft versus host disease prophylaxis is mandatory
Hydration: Routine hydration recommended
Hypersensitivity / Infusion related reaction risk: High - routine premedication recommended
Irradiated blood components: Irradiation of blood components is recommended
Mesna uroprotection: Routine mesna uroprotection recommended
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: Routine antibiotic prophylaxis recommended
Sinusoidal obstruction syndrome prophylaxis: Sinsuoidal obstruction prophylaxis may be considered
Tumour lysis syndrome prophylaxis: Tumour lysis syndrome prophylaxis may be considered

Antifungal prophylaxis: Inhibition of CYP3A4 by azole antifungals will lead to reduced ciclosPORIN clearance and increased toxicities. A reduced ciclosPORIN dose is required with close monitoring of ciclosPORIN levels—see prescribing information, or Interactions checker in the NZ Formulary (nzf.org.nz).


CMV monitoring:

  • If allograft recipient +/- donor are CMV seropositive:
  • CMV quantitative PCR monitoring of CMV viral load should commence day 14 and be repeated once a week.
  • Evidence of CMV reactivation necessitates appropriate antiviral treatment. 

Emetogenicity:

  • MEDIUM days -6 and -5;
  • MINIMAL days -4, -3 and -2;
  • Radiotherapy-induced nausea and vomiting (RINV) day -1;
  • HIGH days +3 and +4.

 

References

Powles, R. L., G. R. Morgenstern, H. E. Kay, et al. 1983. "Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia." Lancet 1(8325):612-615., PMID: 6131300

Mehta, J., S. Singhal, A. P. Gee, et al. 2004. "Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients." Bone Marrow Transplant 33(4):389-396., PMID: 14716338

Aversa, F., A. Tabilio, A. Velardi, et al. 1998. "Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype." N Engl J Med 339(17):1186-1193., PMID: 9780338

Rizzieri, D. A., L. P. Koh, G. D. Long, et al. 2007. "Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution." J Clin Oncol 25(6):690-697., PMID: 17228020

Huang, X. J., D. H. Liu, K. Y. Liu, et al. 2009. "Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation." Biol Blood Marrow Transplant 15(2):257-265., PMID: 19167686

Ruggeri, L., A. Mancusi, M. Capanni, et al. 2007. "Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value." Blood 110(1):433-440., PMID: 17371948

O'Donnell, P. V., L. Luznik, R. J. Jones, et al. 2002. "Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide." Biol Blood Marrow Transplant 8(7):377-386., PMID: 12171484

Luznik, L., L. W. Engstrom, R. Iannone, et al. 2002. "Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation." Biol Blood Marrow Transplant 8(3):131-138., PMID: 11939602

Mayumi, H., M. Umesue and K. Nomoto. 1996. "Cyclophosphamide-induced immunological tolerance: an overview." Immunobiology 195(2):129-139., PMID: 8877390

Luznik, L., P. V. O'Donnell, H. J. Symons, et al. 2008. "HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide." Biol Blood Marrow Transplant 14(6):641-650., PMID: 18489989

McCurdy, S. R., J. A. Kanakry, M. M. Showel, et al. 2015. "Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide." Blood 125(19):3024-3031., PMID: 25814532

Raj, K., A. Pagliuca, K. Bradstock, et al. 2014. "Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning." Biol Blood Marrow Transplant 20(6):890-895., PMID: 24650678

Castagna, L., R. Crocchiolo, S. Furst, et al. 2014. "Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide." Biol Blood Marrow Transplant 20(5):724-729., PMID: 24530426

Bashey, A., X. Zhang, C. A. Sizemore, et al. 2013. "T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation." J Clin Oncol 31(10):1310-1316., PMID: 23423745

Di Stasi, A., D. R. Milton, L. M. Poon, et al. 2014. "Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors." Biol Blood Marrow Transplant 20(12):1975-1981., PMID: 25263628

Raiola, A. M., A. Dominietto, C. di Grazia, et al. 2014. "Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts." Biol Blood Marrow Transplant 20(10):1573-1579., PMID: 24910379

Ciurea, S. O., M. J. Zhang, A. A. Bacigalupo, et al. 2015. "Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia." Blood 126(8):1033-1040., PMID: 26130705

Bubalo J, Carpenter PA, et al; American Society for Blood and Marrow Transplantation practice guideline committee. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi: 10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23. , PMID: 24462742

New Zealand Blood Service Transfusion Medicine Handbook Third Edition, 2016 https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/111G122.pdf (accessed 16 June 2022)

Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Med J Aust. 2019 Jun;210(10):462-468. doi: 10.5694/mja2.50160. Epub 2019 May 19. , PMID: 31104328

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.